Surrozen (NASDAQ:SRZN) Major Shareholder Acquires $91,356.69 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 4,271 shares of the business’s stock in a transaction on Friday, January 30th. The stock was acquired at an average price of $21.39 per share, with a total value of $91,356.69. Following the acquisition, the insider owned 639,141 shares in the company, valued at $13,671,225.99. The trade was a 0.67% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc bought 4,355 shares of Surrozen stock. The shares were bought at an average price of $21.94 per share, for a total transaction of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The stock was bought at an average price of $21.38 per share, with a total value of $15,628.78.

Surrozen Stock Performance

NASDAQ:SRZN opened at $21.25 on Friday. Surrozen, Inc. has a one year low of $5.90 and a one year high of $25.47. The stock has a market cap of $182.11 million, a PE ratio of -0.95 and a beta of 0.58. The stock has a 50 day moving average price of $20.81 and a 200 day moving average price of $15.14.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The company had revenue of $0.98 million during the quarter. As a group, analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of SRZN. China Universal Asset Management Co. Ltd. boosted its stake in Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after buying an additional 500 shares during the period. Citadel Advisors LLC raised its stake in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of Surrozen during the 2nd quarter worth approximately $536,000. Finally, Woodline Partners LP purchased a new position in shares of Surrozen during the 3rd quarter worth approximately $621,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SRZN. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.